Lutetium-177-PSMA therapy for prostate cancer patients—abrief overview of the literature Radioligand therapy with lutetium-177 prostate specific membrane antigen ([177Lu]Lu-PSMA) represents apromising treatment for metastatic castration-resista... LWMV Kalmthout,ECAVD Sar,AJAT Braat,... - 《Tijds...
23, 2022, the FDA approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto; Novartis), which is referred to in nuclear medicine literature as 177Lu–prostate-specific membrane antigen–617 (177Lu PSMA-617), for the treatment of PSMA-positive metastatic castration resistant p...
Prostate Cancer | Image Credit: © SciePro - stock.adobe.com Treatment with the combination of lutetium Lu 177 vipivotide tetraxetan (Pluvicto; formerly 177Lu-PSMA-617) and enzalutamide (Xtandi) led to an improvement in prostate-specific antigen (PSA) progression-free survival (PSA-PFS...
This work uses the Monte Carlo method in prostate cancer radiation planning systems. • MCNP6 simulates two different treatments: Brachytherapy with 125I seeds and radiolabeled 177Lu-PSMA. • A 3D model of the anatomy of a real anonymized patient is created from the segmentation of CT images...
Lu 177 psma therapy can be used for metastatic cancer. Unfortunately, only a few countries worldwide can offer this innovative prostate cancer treatment. Experience – German specialists were the first who started to treat patients with prostate cancer using radionuclide methods. ...
Dr.Andrew Tan, Nuclear Medicine Physician and Head, NMS said: "Lutetium-177 PSMA Therapy offers another form of prostate cancer treatment for advanced stage patients. This form of targeted cancer radiotherapy has been shown to achieve good biochemical (PSA) responses ...
The shift towards non-carrier-added Lutetium-177 is driven by its higher purity and effectiveness in targeted therapies, reducing side effects and radioactive waste. Its applications in cancer treatment, particularly for NETs and...
The shift towards non-carrier-added Lutetium-177 is driven by its higher purity and effectiveness in targeted therapies, reducing side effects and radioactive waste. Its applications in cancer treatment, particularly for NETs ...
Background: This study aims to analyze the prognostic importance of serum PSA response in patients who received radioligand therapy (RLT) with Lu-177 Prostate-specific membrane antigen (PSMA) for their castration-resistant prostate cancer. Methods: Thirty consecutive patients who received Lu-177 PSMA...
The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-free survival (PFS) and postpone the need for androgen deprivation ther...